Early phase development services that will enable informed decision making for your drug development programme.
ICON has a large early phase clinical research network with 6 state-of-the-art facilities in North America and the Netherlands. Each clinic is supported by the expertise required to successfully deliver the most complex of healthy volunteer, patient, or hybrid first-in-human and proof-of-concept studies.
We provide customised solutions designed to evaluate clinical endpoints and biomarkers within a smaller sample of patients to provide you with reliable proof of concept data and enable go/no go decisions in a timely manner.
ICON is committed to the highest standards of excellence and scientific expertise in early clinical drug development.
We have extensive experience in the design, conduct, and interpretation of Phase 1/1a/proof of concept studies, providing the full suite of clinical pharmacology studies, all elements of a regulatory package programme, and translational early efficacy indication solutions in a range of study types including:
ICON’s early clinical services deliver full visibility and control to meet the requirements of increasingly complex clinical trial requirements. Our dedicated early phase specialists will engage with you to develop a trial that is best for your compound. Together we will build a tailored approach that leverages our clinical pharmacology expertise, extensive research facilities, early phase operational experience, and biometrics capabilities to conduct your trial within both healthy volunteers and patient populations.
We help design a protocol that works harder and smarter for you.
Providing pivotal information on efficacy, dose-response and time-effects of drugs.
A one stop drug development solution that is perfectly suited for early phase trials with shorter timelines.
Supporting rapid in-house simple analysis with method development, assay validation and specimen analysis.
Network of ICON-owned clinics with the ability to deliver the most complex of healthy volunteer, patient, or hybrid first-in-human and proof-of-concept studies.
Specialised data management, programming, biostatistics and medical writing services
Customised solutions designed to evaluate clinical endpoints and biomarkers within a smaller sample of patients to provide you with reliable proof of concept data.